Kyowa Hakko’s Citicoline obtains Novel Food Registration status in Europe

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI) and concluded that Citicoline is safe under the proposed uses and use levels (www.efsa.europa.eu/it/efsajournal/doc/3421.pdf ).

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising Kyowa Hakko Europe the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_196_R_0006&from=EN ).

Citicoline is intended to be used in food supplements aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1 000 mg/day.

In United States, Kyowa Hakko USA, Inc. offers a proprietary form of Citicoline, Cognizin®, a pure, allergen-free GRAS ingredient that’s stable and effective. For more information, go to www.cognizin.com .